UBS Group
KLRS

UBS Group’s Kalaris Therapeutics KLRS Stock Holding History

UBS Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.7K Buy
6,184
+3,493
+130% +$31K ﹤0.01% 7588
2025
Q4 		$22.7K Sell
2,691
-2,561
-49% -$16.4K ﹤0.01% 7694
2025
Q3 		$30.4K Buy
5,252
+1,136
+28% +$3.75K ﹤0.01% 7889
2025
Q2 		$11K Sell
4,116
-5,145
-56% -$23.2K ﹤0.01% 8806
2025
Q1 		$74.4K Buy
9,261
+3,804
+70% +$37.2K ﹤0.01% 7276
2024
Q4 		$52.7K Buy
5,457
+5,360
+5,526% +$81.1K ﹤0.01% 7263
2024
Q3 		$1.8K Sell
97
-1,524
-94% -$26.7K ﹤0.01% 8549
2024
Q2 		$27K Sell
1,621
-792
-33% -$14K ﹤0.01% 7119
2024
Q1 		$41.9K Sell
2,413
-223
-8% -$3.64K ﹤0.01% 6591
2023
Q4 		$41.2K Buy
2,636
+1,060
+67% +$41.8K ﹤0.01% 6657
2023
Q3 		$78K Buy
1,576
+1,223
+346% +$83.3K ﹤0.01% 5999
2023
Q2 		$27.6K Sell
353
-349
-50% -$33.2K ﹤0.01% 6749
2023
Q1 		$63.6K Sell
702
-121
-15% -$15.4K ﹤0.01% 6266
2022
Q4 		$97.1K Buy
823
+787
+2,186% +$133K ﹤0.01% 6130
2022
Q3 		$6K Sell
36
-9
-20% -$1.4K ﹤0.01% 9086
2022
Q2 		$4K Hold
45
– – ﹤0.01% 9158
2022
Q1 		$7K Sell
45
-2,733
-98% -$545K ﹤0.01% 8857
2021
Q4 		$827K Buy
2,778
+863
+45% +$400K ﹤0.01% 4551
2021
Q3 		$1.1M Buy
1,915
+1,129
+144% +$523K ﹤0.01% 4113
2021
Q2 		$357K Sell
786
-2,337
-75% -$1.21M ﹤0.01% 4963
2021
Q1 		$1.68M Buy
3,123
+3,111
+25,925% +$2.61M ﹤0.01% 3749
2020
Q4 		$11K Sell
12
-32
-73% -$24.6K ﹤0.01% 7436
2020
Q3 		$28K Buy
+44
New +$30K ﹤0.01% 6049

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

UBS Group's KLRS Position: Q1 2026 in Review

UBS Group increased its Kalaris Therapeutics (KLRS) stake by 130% in Q1 2026, buying an estimated $31K and bringing the position to 6,184 shares worth $35.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7588.

UBS Group first reported a position in KLRS in Q3 2020 and has held it in 23 quarters since. The position peaked at $1.68M in Q1 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • UBS Group held 6,184 shares of Kalaris Therapeutics worth $35.7K as of Q1 2026.
  • UBS Group bought 3,493 Kalaris Therapeutics shares in Q1 2026, an estimated $31K.
  • Kalaris Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7588 holding.
  • UBS Group first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • UBS Group's Kalaris Therapeutics position peaked at $1.68M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.